Inhaled liposomal amikacin. (Q38216555)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882271%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

Inhaled liposomal amikacin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882271%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882271%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

Valerie Waters

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882271%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

publication date

31 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882271%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Respiratory Medicine

19 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882271%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882271%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882271%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

401-409

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882271%20AND%20SRC:MED&resulttype=core&format=json

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

19 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Determinants of mortality from cystic fibrosis in Canada, 1970-1989.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against gram-negative and gram-positive bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Biofilms, antimicrobial resistance, and airway infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Nontuberculous mycobacterial infection in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Mycobacterium abscessus and children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Antibiotic susceptibility pattern of rapidly growing mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

Ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2014.918507

10.1586/17476348.2014.918507

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24882271%20AND%20SRC:MED&resulttype=core&format=json

release_qybiuf3ki5direnwcsibnsge7a

19 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qybiuf3ki5direnwcsibnsge7a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference